|
Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration. |
|
|
No Relationships to Disclose |
|
|
Employment - AgNovos (I); Qiagen (I); Regulatory and Quality Solutions (I) |
|
|
|
Stock and Other Ownership Interests - GlaxoSmithKline; IQVIA |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - COTA Healthcare |
Stock and Other Ownership Interests - Abbvie; COTA Healthcare; Johnson & Johnson; UnitedHealthcare |
|
|
|
Stock and Other Ownership Interests - United Health Group |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb; Cota Healthcare |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Cota Healthcare |
|
|
|
Stock and Other Ownership Interests - Syapse |
Travel, Accommodations, Expenses - Syapse |
|
|
No Relationships to Disclose |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Roche |
|
|
|
|
Honoraria - Bristol-Myers Squibb; Roche |
Consulting or Advisory Role - Advi; Boehringer Ingelheim; Bristol-Myers Squibb; New Century Health |
Research Funding - Side-Out Foundation (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Syapse |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |